- Home
- FBYD vs GNLX Comparison
FBYD vs GNLX Comparison
Compare FBYD & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBYD
- GNLX
- Stock Information
- Founded
- FBYD 2021
- GNLX 2001
- Country
- FBYD United States
- GNLX United States
- Employees
- FBYD N/A
- GNLX N/A
- Industry
- FBYD
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- FBYD
- GNLX Health Care
- Exchange
- FBYD Nasdaq
- GNLX Nasdaq
- Market Cap
- FBYD 120.8M
- GNLX 103.6M
- IPO Year
- FBYD N/A
- GNLX 2023
- Fundamental
- Price
- FBYD $9.49
- GNLX $2.36
- Analyst Decision
- FBYD
- GNLX Strong Buy
- Analyst Count
- FBYD 0
- GNLX 4
- Target Price
- FBYD N/A
- GNLX $18.25
- AVG Volume (30 Days)
- FBYD 11.4K
- GNLX 169.7K
- Earning Date
- FBYD 11-14-2024
- GNLX 11-14-2024
- Dividend Yield
- FBYD N/A
- GNLX N/A
- EPS Growth
- FBYD N/A
- GNLX N/A
- EPS
- FBYD N/A
- GNLX N/A
- Revenue
- FBYD $7,042,000.00
- GNLX $8,000.00
- Revenue This Year
- FBYD N/A
- GNLX N/A
- Revenue Next Year
- FBYD N/A
- GNLX N/A
- P/E Ratio
- FBYD N/A
- GNLX N/A
- Revenue Growth
- FBYD N/A
- GNLX N/A
- 52 Week Low
- FBYD $7.02
- GNLX $1.60
- 52 Week High
- FBYD $14.25
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- FBYD 47.87
- GNLX 37.36
- Support Level
- FBYD $9.00
- GNLX $2.86
- Resistance Level
- FBYD $9.79
- GNLX $3.07
- Average True Range (ATR)
- FBYD 0.68
- GNLX 0.31
- MACD
- FBYD 0.02
- GNLX -0.07
- Stochastic Oscillator
- FBYD 41.45
- GNLX 2.56
About FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has five operating segments, Falcon's Creative Group, PDP, Sierra Parima, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.